Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

NCT00678119 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: AGS-003
DRUG: Sunitinib

Sponsor

Argos Therapeutics